The addition of Rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL):: Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG).

被引：0
|
作者：
Hiddemann, W [1 ]
Unterhalt, M [1 ]
Dreyling, M [1 ]
Hossfeld, DK [1 ]
Lengfelder, E [1 ]
Metzner, B [1 ]
Pfreundschuh, M [1 ]
Kneba, M [1 ]
Fricke, HJ [1 ]
Böck, HP [1 ]
Schmitz, N [1 ]
Koch, P [1 ]
Fuchs, R [1 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, GLSG, D-8000 Munich, Germany
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
339
引用
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
  • [31] The addition of rituximab to frontline chop significantly improves time to treatment failure and response duration in all flipi risk groups of patients with advanced-stage follicular lymphoma: Results of a randomized trial of the german low-grade lymphoma study group
    Hoster, E.
    Unterhalt, M.
    Buske, C.
    Dreyling, M.
    Hiddemann, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
  • [32] Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months.
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Reiser, Marcel
    Lengfelder, Eva
    Woermann, Bernhard J.
    Harder, Harriet
    Hegewisch-Becker, Susanna
    Berdel, Wolfgang E.
    Hess, Georg
    Eimermacher, Hartmut
    Aldaoud, Ali
    Planker, Manfred
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2008, 112 (11) : 901 - 901
  • [33] Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)
    Weigert, Oliver
    Uysal, Atakan
    Metzner, Bernd
    Pfreundschuh, Michael
    Schmitz, Norbert
    Wandt, Hannes
    Peschel, Christian
    Hoster, Eva
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2008, 112 (11) : 764 - 764
  • [34] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    BLOOD, 2005, 106 (12) : 3725 - 3732
  • [35] Bendamustine/mitoxantrone/rituximab (BMR):: A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas.: Results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide, R
    Heymanns, J
    Thomalla, J
    Köppler, H
    Hess, G
    Aldaoud, A
    Schmitz, S
    Unterhalt, M
    Dreyling, MH
    Hiddemann, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 589S - 589S
  • [36] Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin H.
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Hallek, Michael
    Lengfelder, Eva
    Hiddemann, Wolfgang
    Unterhalt, Michael
    BLOOD, 2009, 114 (22) : 1427 - 1427
  • [37] The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial
    Hoster, Eva
    Unterhalt, Michael
    Woermann, Bernhard
    Duehrsen, Ulrich
    Metzner, Bernd
    Eimermacher, Hartmut
    Neubauer, Andreas
    Wandt, Hannes
    Steinhauer, Hjalmar
    Martin, Sonja
    Heidemann, Else
    Aldrioud, Ali
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2008, 112 (11) : 1048 - 1048
  • [38] Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
    Scheubeck, Gabriel
    Hoffmann, Martin
    Jurinovic, Vindi
    Fischer, Luca
    Unterhalt, Michael
    Schmidt, Christian
    Boeck, Hans-Peter
    Duehrsen, Ulrich
    Kaesberger, Joachim
    Kremers, Stephan
    Lindemann, Hans-Walter
    Mantovani, Luisa
    Hiddemann, Wolfgang
    Hoster, Eva
    Dreyling, Martin
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2373 - 2380
  • [39] Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG))
    Herfarth, Klaus
    Engelhard, Marianne
    Borchmann, Peter
    Hohloch, Karin
    Budach, Volker
    Viardot, Andreas
    Witzens-Harig, Mathias
    Eich, Hans
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2012, 120 (21)
  • [40] Treatment of mantle cell lymphoma (MCL) by allogeneic stem cell transplantation - results from the prospective trials #060 and #074 of the East German Study Group for Haematology and Oncology (OSHO)
    Krueger, W. H.
    Basara, N.
    Hirt, C.
    Niederwieser, D.
    Behre, G.
    Grobe, N.
    Sayer, H.
    Maschmeyer, G.
    Haas, A.
    Fischer, T.
    Kiehl, M.
    Busemann, C.
    Doelken, G.
    ONKOLOGIE, 2011, 34 : 70 - 72
12345